×
About 1,840 results

ALLMedicine™ Primary Myelofibrosis Center

Research & Reviews  647 results

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

May 13th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or...
https://clinicaltrials.gov/ct2/show/NCT04485260

May 9th, 2022 - This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose...

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
https://clinicaltrials.gov/ct2/show/NCT01387763

Apr 27th, 2022 - Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem c...

Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary mye...
https://doi.org/10.1007/s12185-022-03331-x 10.1038/s41379-018-0014-x 10.5858/2007-131-1719-TOPVTC 10.3816/CLM.2009.n.080 10.1111/ijlh.12398 10.1038/modpathol.2017.182 10.1007/s00277-016-2827-3 10.1182/blood-2014-12-616847 10.1182/blood-2006-12-061135 10.1056/NEJMc1413718 10.1080/10428194.2019.1639162 10.1093/ajcp/aqy050 10.3324/haematol.2018.202952 10.1056/NEJMoa1311347 10.1038/s41375-020-01037-9
International Journal of Hematology; Sobieralski P, Bieniaszewska M et. al.

Apr 17th, 2022 - Development of secondary CML has only been casually described, with few reports attempting to analyze and explain the mechanisms behind this phenomenon. Reported cases vary with regard to presumed pathogenesis and clinical characteristics, but sim...

see more →

Guidelines  1 results

Guideline for the diagnosis and management of myelofibrosis.
https://doi.org/10.1111/j.1365-2141.2012.09179.x
British Journal of Haematology; Reilly JT, McMullin MF et. al.

Jun 2nd, 2012 - The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematica...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  33 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

May 13th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or...
https://clinicaltrials.gov/ct2/show/NCT04485260

May 9th, 2022 - This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose...

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
https://clinicaltrials.gov/ct2/show/NCT01387763

Apr 27th, 2022 - Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem c...

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
https://clinicaltrials.gov/ct2/show/NCT05153343

Mar 15th, 2022 - Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that ...

see more →

News  53 results

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis
https://www.onclive.com/view/pacritinib-paves-a-unique-lane-of-treatment-for-select-myelofibrosis

Apr 5th, 2022 - Patients who develop post–essential thrombocythemia myelofibrosis (PET-MF) or post–polycythemia vera myelofibrosis (PPV-MF), which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effecti...

Rapidly Enlarging Bullous Plaque
https://www.mdedge.com/dermatology/article/252463/dermatopathology/rapidly-enlarging-bullous-plaque
Marina Kristy Ibraheim, MD, Katherine Martin, MD et. al.

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia
https://www.onclive.com/view/fda-extends-review-period-for-pacritinib-for-myelofibrosis-with-severe-thrombocytopenia

Nov 30th, 2021 - The FDA has extended the review period for the new drug application (NDA) for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosi...

Treatment Strategies for Primary Myelofibrosis
https://www.onclive.com/view/treatment-strategies-for-primary-myelofibrosis

Sep 1st, 2021 - Srdan Verstovsek, MD, PhD: In 2019, fedratinib was approved and then incorporated into the national guidelines, these are the NCCN [National Comprehensive Cancer Network] guidelines. It was listed as a drug that can be used in the frontline settin...

Overview of Primary Myelofibrosis
https://www.onclive.com/view/overview-of-primary-myelofibrosis

Aug 30th, 2021 - Srdan Verstovsek, MD, PhD: Primary myelofibrosis has different signs and symptoms, but the 3 classic ones are, No. 1, bone marrow failure that represents itself with anemia in particular. No. 1 is the anemia. The second one is the symptomatic sple...

see more →

Patient Education  1 results see all →